<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33730844</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1592-8721</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>106</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Haematologica</Title>
          <ISOAbbreviation>Haematologica</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>2364</StartPage>
          <EndPage>2373</EndPage>
          <MedlinePgn>2364-2373</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2020.272500</ELocationID>
        <Abstract>
          <AbstractText>B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhibitor that may be better tolerated by patients who are intolerant to ibrutinib. A phase 2 study of acalabrutinib was conducted in patients with relapsed/refractory CLL who were ibrutinib-intolerant and had continued disease activity. Intolerance was defined as having discontinued ibrutinib due to persistent grade 3/4 adverse events (AEs) or persistent/recurrent grade 2 AEs despite dose modification/interruption. Patients received oral acalabrutinib 100 mg twice daily until disease progression or intolerance. Sixty patients were treated. Overall response rate to acalabrutinib was 73% and three patients (5%) achieved complete remission. At median follow-up of 35 months, the median progressionfree and overall survival were not reached; 24-month estimates were 72% and 81%, respectively. The most frequent AEs with acalabrutinib were diarrhea (53%), headache (42%), contusion (40%), dizziness (33%), upper respiratory tract infection (33%), and cough (30%). Most common reasons for acalabrutinib discontinuation were progressive disease (23%) and AEs (17%). Most patients with baseline samples (49/52; 94%) and all with on-treatment samples (3/3; 100%) had no detectable BTK and/or PLCG2 mutations. Acalabrutinib is effective and tolerable in most patients with relapsed/refractory CLL who are intolerant of ibrutinib. Acalabrutinib may be useful for patients who may benefit from BTK inhibitor therapy but are ibrutinib intolerant.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rogers</LastName>
            <ForeName>Kerry A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University, Columbus, OH. Kerry.Rogers@osumc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thompson</LastName>
            <ForeName>Philip A</ForeName>
            <Initials>PA</Initials>
            <AffiliationInfo>
              <Affiliation>MD Anderson Cancer Center, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Allan</LastName>
            <ForeName>John N</ForeName>
            <Initials>JN</Initials>
            <AffiliationInfo>
              <Affiliation>Weill Cornell Medicine, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coleman</LastName>
            <ForeName>Morton</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Weill Cornell Medicine, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharman</LastName>
            <ForeName>Jeff P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Willamette Valley Cancer Institute, Eugene, OR.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheson</LastName>
            <ForeName>Bruce D</ForeName>
            <Initials>BD</Initials>
            <AffiliationInfo>
              <Affiliation>Georgetown University Hospital, Washington, DC.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jones</LastName>
            <ForeName>Daniel</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>The Ohio State University, Columbus, OH.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Izumi</LastName>
            <ForeName>Raquel</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frigault</LastName>
            <ForeName>Melanie M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quah</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raman</LastName>
            <ForeName>Rakesh K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Priti</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Min Hui</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Acerta Pharma, South San Francisco, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kipps</LastName>
            <ForeName>Thomas J</ForeName>
            <Initials>TJ</Initials>
            <AffiliationInfo>
              <Affiliation>UC San Diego Moores Cancer Center, San Diego, CA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02717611</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA016058</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Haematologica</MedlineTA>
        <NlmUniqueID>0417435</NlmUniqueID>
        <ISSNLinking>0390-6078</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X70OSD4VX</RegistryNumber>
          <NameOfSubstance UI="C551803">ibrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>JAC85A2161</RegistryNumber>
          <NameOfSubstance UI="D000225">Adenine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Haematologica. 2021 Sep 01;106(9):2300-2301</RefSource>
          <PMID Version="1">33730846</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000225" MajorTopicYN="N">Adenine</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="Y">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>4</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33730844</ArticleId>
        <ArticleId IdType="pmc">PMC8409022</ArticleId>
        <ArticleId IdType="doi">10.3324/haematol.2020.272500</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5817726</ArticleId>
            <ArticleId IdType="pubmed">29455639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SE, Gordon AL, Hertlein E, et al. . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3122947</ArticleId>
            <ArticleId IdType="pubmed">21422473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Bojnik E, Ruppert AS, et al. . Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123(8):1207-1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3931190</ArticleId>
            <ArticleId IdType="pubmed">24311722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SEM, Montraveta A, Niemann CU, et al. . The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11): 2831-2841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5548968</ArticleId>
            <ArticleId IdType="pubmed">27903679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Furman RR, Coutre SE, et al. . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3772525</ArticleId>
            <ArticleId IdType="pubmed">23782158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Nabhan C, Thompson MC, et al. . Toxicities and outcomes of 616 ibrutinibtreated patients in the United States: a realworld analysis. Haematologica. 2018;103(5): 874-879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5927982</ArticleId>
            <ArticleId IdType="pubmed">29419429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016;12(11):1381-1392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5391303</ArticleId>
            <ArticleId IdType="pubmed">27686109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma version 2.2021. December 3, 2020. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed December 21, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>O'Brien S, Furman RR, Coutre S, et al. . Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910-1919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5921964</ArticleId>
            <ArticleId IdType="pubmed">29437592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calquence approved in the US for adult patients with chronic lymphocytic leukaemia [press release]. 2019. Available from: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/calquence-approved-in-theus-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. Accessed December 21, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O'Brien S, et al. . Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323-332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bye AP, Unsworth AJ, Desborough MJ, et al. . Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1(26):2610-2623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5728643</ArticleId>
            <ArticleId IdType="pubmed">29296914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barf T, Covey T, Izumi R, et al. . Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363(2):240-252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Brown JR, O'Brien S, et al. . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghia P, Pluta A, Wach M, et al. . ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849-2861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32459600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Awan FT, Schuh A, Brown JR, et al. . Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3(9): 1553-1562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6517672</ArticleId>
            <ArticleId IdType="pubmed">31088809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallek M, Cheson BD, Catovsky D, et al. . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12): 5446-5456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972576</ArticleId>
            <ArticleId IdType="pubmed">18216293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Ruppert AS, Guinn D, et al. . BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437-1443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5455463</ArticleId>
            <ArticleId IdType="pubmed">28418267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones D, Woyach JA, Zhao W, et al. . PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment. Leukemia. 2017;31(7):1645-1647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28366935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Wierda WG, Schuh A, et al. . Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204-1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7146022</ArticleId>
            <ArticleId IdType="pubmed">31876911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach JA, Furman RR, Liu TM, et al. . Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4144824</ArticleId>
            <ArticleId IdType="pubmed">24869598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woyach J, Huang Y, Rogers K, et al. . Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations. Blood. 2019;134(Suppl 1):504.</Citation>
        </Reference>
        <Reference>
          <Citation>Albitar A, Ma W, DeDios I, et al. . Using highsensitivity sequencing for the detection of mutations in BTK and PLCgamma2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. Oncotarget. 2017;8(11): 17936-17944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5392298</ArticleId>
            <ArticleId IdType="pubmed">28212557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu TM, Woyach JA, Zhong Y, et al. . Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon Bcell receptor activation. Blood. 2015;126(1): 61-68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4492196</ArticleId>
            <ArticleId IdType="pubmed">25972157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Brien S, Furman RR, Coutre SE, et al. . Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48-58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134524</ArticleId>
            <ArticleId IdType="pubmed">24332241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Series J, Garcia C, Levade M, et al. . Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica. 2019;104(11):2292-2299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6821604</ArticleId>
            <ArticleId IdType="pubmed">30819914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Nabhan C, Barr PM, et al. . Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18): 2199-2205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27601462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mato AR, Schuster SJ, Lamanna N, et al. . A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3KÎ´ inhibitor therapy. Hematol Oncol. 2019;37(s2):88-89.</Citation>
        </Reference>
        <Reference>
          <Citation>Ghia P, Pluta A, Wach M, et al. . ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849-2861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32459600</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
